布瑞哌唑; 依匹哌唑； Brexpiprazole；913611-97-9

产品描述

Ÿ   等级：活性药物成分（API）

Ÿ   化学名称:7 - [4 - (4 - (1-benzothiophen-4-yl) piperazin-1-yl)丁氧基)1 h-quinolin-2-one

Ÿ   分子式:C25H27N3O2S

Ÿ   分子量:433.566

Ÿ   规范：按照ChP/USP/EP建立企业标准

Ÿ   外观:粉

Ÿ   总杂质：不大于0.5%

Ÿ   纯度：不低于99%

Ÿ   残留溶剂：完全符合ICH Q3C要求

Ÿ   致突变杂质：完全符合ICH M8

Ÿ   亚硝胺评估：可用

Ÿ   粒度：可根据客户要求进行普通级或研磨/筛分。

Ÿ   储存方法：室温

Ÿ   生产能力：

Ÿ   标准包装：1kg/袋，5kg/袋，或根据客户要求

产品用途

Ÿ  rexpiprazole API是一种非典型抗精神病药物，也是一种新型D2多巴胺和5 -羟色胺-多巴胺活性调节剂（SDAM）。它对血清素、多巴胺和α (α)-肾上腺素能受体有很高的亲和力。虽然其结构与阿立哌唑相似，但brexpiprazole对多巴胺和血清素受体的结合亲和力不同。与阿立哌唑相比，brexpiprazole的部分激动剂介导的不良反应（如锥体外系症状）的可能性较小，这是由于D2受体的内在活性较低。它对5-HT1A和5-HT2A受体也表现出更强的拮抗作用。

Brexpiprazole于2015年7月10日首次获得FDA批准。目前，brexpiprazole已被批准用于治疗抑郁症、精神分裂症和与阿尔茨海默病引起的痴呆相关的躁动，同时也被用于其他精神疾病的研究，如创伤后应激障碍。

联系方式

四川青木制药有限公司

四川省眉山市东坡区经济开发区东区顺江大道南段55号

国际营销部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

国内营销部(Mainland)：

李经理 13880480517   

杨经理 15982276454

Product Description

• Grade: Active Pharmaceutical Ingredient(API)

• Chemical Name:7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one

• Molecular Formula:C25H27N3O2S

• Molecular Weight:433.566

• Specification: Enterprise Standard established according      to ChP/USP/EP

• Appearance: Powder

• Total impurities: not more than 0.5%

• Purity: not less than 99%

• Residual Solvents: fully comply with ICH Q3C

• Mutagenic impurities: fully comply with ICH M8

• Nitrosamine assessment: available

• Particle size: regular grade or milling/sieving according      to customer’s requirement.

• Storage: Room temperature

• Production capacity: Commercial

• Standard Package: 1kg/bag, 5kg/bag, or according to the      customer’s requirement

Applications 

• Brexpiprazole API is an atypical antipsychotic and a novel D2      dopamine and serotonin 1A partial agonist called serotonin-dopamine      activity modulator (SDAM). It has a high affinity for serotonin, dopamine,      and alpha (α)-adrenergic receptors. Although it is structurally similar to      aripiprazole, brexpiprazole has different binding affinities for dopamine      and serotonin receptors. Compared to aripiprazole, brexpiprazole has less      potential for partial agonist-mediated adverse effects such as      extrapyramidal symptoms, which is attributed to lower intrinsic activity      at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and      5-HT2A receptors.

• Brexpiprazole was first approved by the FDA on July      10, 2015. Currently approved for the treatment of depression,      schizophrenia, and agitation associated with dementia due to Alzheimer’s      disease, brexpiprazole has also been investigated in other psychiatric      disorders, such as post-traumatic stress disorder.

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187